Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DarioHealth (DRIO) EBITDA (2016 - 2025)

DarioHealth filings provide 13 years of EBITDA readings, the most recent being -$10.3 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 16.39% to -$10.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$61.7 million, a 50.64% decrease, with the full-year FY2025 number at -$61.7 million, down 50.64% from a year prior.
  • EBITDA hit -$10.3 million in Q4 2025 for DarioHealth, up from -$18.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.9 million in Q2 2024 to a low of -$22.9 million in Q3 2021.
  • Median EBITDA over the past 5 years was -$15.8 million (2022), compared with a mean of -$15.4 million.
  • Biggest five-year swings in EBITDA: tumbled 342.71% in 2021 and later soared 73.17% in 2024.
  • DarioHealth's EBITDA stood at -$22.1 million in 2021, then skyrocketed by 41.63% to -$12.9 million in 2022, then dropped by 20.37% to -$15.5 million in 2023, then grew by 20.93% to -$12.3 million in 2024, then rose by 16.39% to -$10.3 million in 2025.
  • The last three reported values for EBITDA were -$10.3 million (Q4 2025), -$18.9 million (Q3 2025), and -$18.6 million (Q2 2025) per Business Quant data.